BPC-157 + TB-500
5 mg + 5 mg
Combination studied in soft-tissue repair research (tendon, ligament and muscle). BPC-157 has been investigated for angiogenesis and inflammatory signaling; TB-500 for cell-migration processes.
- Studied in tissue-repair models
- Investigated for local inflammatory signaling
- Studied in joint and tendon research
- Investigated in gastrointestinal models
Scientific context
Origin, mechanism, and research
BPC-157 is a synthetic pentadecapeptide based on a human gastric-juice sequence, described since 1991-1993 by Predrag Sikiric (University of Zagreb, Croatia), the source of most of its 100+ publications. TB-500 is the synthetic version of a fragment of Thymosin Beta-4, a protein isolated in the 1960s-70s by Allan Goldstein; the full molecule was studied in phase II-III trials by RegeneRx for other uses. Neither has FDA or EMA approval; both are under review by the FDA compounding advisory committee (2026) after being removed from the prohibited list, which does not amount to approval. BPC-157 activates the VEGFR2-Akt-eNOS pathway favoring angiogenesis, while TB-500 regulates cell migration; nearly all the evidence is preclinical, in animal models.
Information for educational and informational purposes, based on public sources; it does not constitute medical advice. Product for laboratory research use only — not for human consumption.
